BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Neutra Corp. NTRR
12 fiscal years on record · USD · FY2022 reported
SEC FILINGS ONLY
Revenue · FY2022
$67,996
▼ 26.1% vs FY2021
EPS · FY22
—
Dividend / sh · FY22
—
Payout · FY22
—
ROE · FY22
—
Net margin · FY22
-825.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 67,996.00
Revenue, FY2022 · full 12-year series below
Revenue
Net income
The company lost 826 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2022
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2022
ROE
Operating margin-437.8%
Net margin-825.7%
Return on assets-544.8%
Returned to shareholders
—
returned in FY2022 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+119.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
2.74B
Shares outstanding, FY2022
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 75,175.00
total assets, end of FY2022
Total assetsUSD 75,175.00
EquityUSD -773,820.00
CashUSD 1,969.00
Current ratio0.03×
Equity funds -1029% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
·
0.0
0.0
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
0.00
0.00
−0.16
−0.10
−0.41
−1.25
−3.36
−0.13
−0.16
−0.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
2.74
1.78
1.49
0.62
0.03
0.01
0.00
0.00
0.00
0.01
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed